Glycosylation is one of the most common post-translational modification mainly taking place in the endoplasmic reticulum (ER) and Golgi apparatus. It has a major impact on the efficacy and stability of biopharmaceuticals. Therefore, antibody glycoengineering is developed as a method to control the composition of glycans and to enhance the pharmacological properties of therapeutic antibodies, including physical stability, immunogenicity, pharmacokinetics and target recognition.
With modern recombination techniques, the genes of a set of specific glycosyltransferases or glycosidases can be systematically knockoutockin or regulated to produce glycoengineered antibodies with more humanized and homogeneous glycosylation, better pharmacokinetics and enhanced pharmacological efficacy.
For instance, by removing the core fucose residue from the Fc region of the antibody, the affinity of the antibody for receptors on immune effector cells will be increased. Besides, the capacity to recruit immune cells such as macrophages/monocytes and Natural Killer (NK) cells will be significantly enhanced. This leads to more effective antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). Thus, the capacity of an antibody to trigger the death of targeted cells is improved.
With the GlycoOpitimize™ platform, Creative Biolabs has developed various glycoengineering services, including Non- or Simplified-Glycosylated Antibodies Service, Low- or Non-Fucosylated Antibodies Service, Over- or De-Sialylated Antibodies Service, In Vitro Enzymic and Chemo-Enzymatic Antibody Glycosylation Remodeling Service, Antibody Glycan Analysis Service, etc.
“Our scientists are fully confident to provide efficient and economically feasible antibody glycoengineering solutions”, introduced Dr. Monika, scientific officer of Creative Biolabs. “We are also able to produce glyco-optimized antibodies in a range of cell lines both for research quantities and in large scale.”
About Creative Biolabs
Creative Biolabs is a biotech service provider of therapeutic antibody discovery and manufacturing, offering high quality service to customers in academia and industry fields all over the world. Its products range from antibody/peptide libraries, biosimilar cell lines, chimeric antigen receptor (CAR) products, conjugate antibodies to engineered antibodies such as therapeutic antibodies, single domain antibodies, bispecific antibodies and intrabodies.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email:Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: http://www.creativebiolabs.net
